Synopsis: Shaily Engineering Plastics is in focus after UBS maintained a Buy rating with a ₹4,000 target, implying ~36% upside. The brokerage highlights growth from GLP-1 injectable demand, Zydus semaglutide approval, vendor diversification in pharma supply chains, compliance-driven outsourcing, and capacity expansion, positioning Shaily as a potential dark horse in injectables.
The shares of a Small-cap company that specialises in high-precision injection molding and the manufacturing of complex, custom-engineered plastic components and assemblies are in focus following the brokerage firm UBS target, which sees 36 percent upside potential.
With a market capitalization of Rs. 13,682.21 crores in the day’s trade, the shares of Shaily Engineering Plastics Ltd rose by 2.5 percent, reaching a high of Rs. 3,005.00 per share compared to its previous closing price of Rs. 2,931.70 per share.
What Happened
Shaily Engineering Plastics Ltd, engaged in high-precision injection moulding and the manufacturing of complex, custom-engineered plastic components and assemblies, is in the spotlight as global brokerage firm UBS maintains a Buy target price of Rs. 4,000, implying about 36 percent upside from the previous close price of Rs. 2,931.70.
Positive read-across from Zydus semaglutide approval
Read-across from Zydus’ semaglutide approval is a major positive for Shaily Engineering Plastics. It signals regulatory acceptance of complex injectable delivery systems. Since Shaily supplies pen components, approval improves confidence in its capabilities, increasing visibility of future orders, revenue growth, and stronger positioning in the high-value GLP-1 drug delivery ecosystem globally.
Vendor diversification opportunity in the pharma supply chain
Vendor change opportunity due to increased regulatory scrutiny in injectable devices benefits Shaily Engineering Plastics. Pharma companies may diversify suppliers to reduce risk concentration. Shaily, with compliant manufacturing capabilities and established relationships, stands to gain incremental contracts, higher utilisation, and improved bargaining power in high-margin pharmaceutical packaging and device segments.
Shift due to compliance and sourcing concerns
Allegations and compliance concerns around prefilled pen device supply chains have led to increased focus on trusted vendors. This creates an opportunity for Shaily Engineering Plastics as pharma companies reassess sourcing partners, prioritising quality assurance, documentation strength, and regulatory compliance, thereby shifting incremental volumes towards reliable and audit-ready manufacturing suppliers globally.
Strong demand from GLP-1 and biologics growth
Growing demand for injectable drug delivery systems, especially GLP-1 therapies and biologics, supports long-term growth prospects. Shaily Engineering Plastics is positioned to benefit from partnerships with global pharma majors, expanding its addressable market, enhancing revenue visibility, and improving scale efficiencies across high-precision plastic components used in drug administration devices globally.
Capacity expansion and operating leverage upside
Capacity expansion, operational leverage, and export demand provide additional upside. Shaily Engineering Plastics can benefit from higher utilisation of existing facilities and new contracts, improving margins over time. Strong relationships with pharmaceutical innovators and increasing outsourcing of device manufacturing further support sustainable earnings growth and re-rating potential in markets globally.
Financials & Others
The company’s revenue rose by 8.72 percent from Rs. 218 crores in March 2025 to Rs. 237 crores in March 2026. Meanwhile, Net profit rose from Rs. 29 crores to Rs. 40 crores in the same period.
The company shows strong financial efficiency with a ROCE of 30.2% and ROE of 28.2%, indicating it is generating healthy returns on the capital it employs as well as on shareholders’ equity. These are generally considered strong profitability metrics, suggesting effective use of resources and solid operational performance.
Its debt-to-equity ratio of 0.27 indicates a relatively low reliance on debt, which reduces financial risk and improves balance sheet stability. Additionally, the company has delivered an impressive 48.9% CAGR profit growth over the last 5 years, reflecting strong and consistent earnings expansion over time.
In Q4 FY26, exports contributed 57.1% of total revenue while domestic sales made up 42.9%, showing a slight tilt toward international markets. This reflects a well-diversified revenue base with stronger dependence on exports.
Shaily Engineering Plastics Limited is India’s largest exporter of plastic components, established in 1987. The company focuses on providing end-to-end solutions in plastic products and services, emphasizing quality, precision, and value creation for stakeholders.
It operates a strong manufacturing base with 7 facilities in Gujarat, including 6 plastic plants and 1 steel furniture unit, supported by 200+ injection moulding machines and highly automated production lines. With over 2,000 employees across its plants, the company demonstrates a sizable and well-integrated operational setup.
Its diversified and de-risked business model, along with advanced manufacturing capabilities, helps it maintain efficiency and scalability while serving both domestic and export markets effectively.
Conclusion: Shaily Engineering Plastics is emerging as a “dark horse” in the injectable devices space due to its strong positioning in high-precision injection molding for drug delivery systems. Rising global demand for GLP-1 therapies and biologics, along with regulatory scrutiny on device quality, is pushing pharma companies to shift toward reliable, compliant suppliers like Shaily.
Brokerage optimism, including UBS’s bullish target, reflects expectations of stronger order inflows, capacity utilisation, and operating leverage. As global pharma firms diversify their vendor base for injectable pen components, Shaily stands to benefit from long-term outsourcing trends. This structural shift could drive sustained growth and re-rating, validating its under-the-radar but high-potential “dark horse” status.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
